% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bohlken:275906,
      author       = {Bohlken, Jens and Kostev, Karel and Michalowsky, Bernhard},
      title        = {{A}lzheimer-{D}emenz und {A}ntidementiva-{V}erordnungen
                      2010–2021 in 357 {H}ausarzt- und 71 {F}acharztpraxen |
                      {A}lzheimer's {D}ementia and {A}nti-{D}ementia {M}edication
                      {P}rescriptions 2010-2021 in 357 {GP} {P}ractices and 71
                      {S}pecialist {P}ractices},
      journal      = {Psychiatrische Praxis},
      volume       = {52},
      number       = {1},
      issn         = {0303-4259},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DZNE-2025-00139},
      pages        = {44 - 47},
      year         = {2025},
      abstract     = {The predicted prevalence of people with dementia (PWD) in
                      Germany has risen to 1.8 million since 2010. In the near
                      future, we will see the approval of antibody therapies. The
                      study aims to demonstrate the recent anti-dementia
                      medication prescriptions and diagnosis prevalence.Data from
                      357 general practitioner (GP) and 71 specialist practices
                      (SP) (1.1 Mio. patients) were analyzed to demonstrate the
                      prevalence of dementia diagnoses and anti-dementia drug
                      prescriptions between 2010 and 2021.The diagnosis prevalence
                      of PWD (Alzheimer's dementia) remained relatively constant
                      in GP practices at $1.0-1.3\%$ $(0.19-0.21\%).$ Among SP,
                      the prevalence increased from $4.9\%$ $(2.8\%)$ to $5.9\%$
                      $(3.6\%).$ The anti-dementia prescription rate decreased in
                      GP (from $0.14\%$ to $0.10\%)$ and increased in SP practices
                      (from $2.1\%$ to $2.4\%).The$ diagnosis and prescription
                      rate, especially in GP practices, remained below the
                      prevalence forecasts and the expected prescriptions.},
      keywords     = {Alzheimer Disease: drug therapy / Alzheimer Disease:
                      epidemiology / Alzheimer Disease: diagnosis / Humans /
                      Germany / Aged / General Practice: statistics $\&$ numerical
                      data / Male / Female / Aged, 80 and over / Practice
                      Patterns, Physicians': statistics $\&$ numerical data /
                      Forecasting / Drug Prescriptions: statistics $\&$ numerical
                      data / Cross-Sectional Studies / Dementia: drug therapy /
                      Dementia: epidemiology / Nootropic Agents: therapeutic use /
                      Nootropic Agents (NLM Chemicals)},
      cin          = {AG Michalowsky},
      ddc          = {610},
      cid          = {I:(DE-2719)5000067},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39384316},
      doi          = {10.1055/a-2370-1933},
      url          = {https://pub.dzne.de/record/275906},
}